446 related articles for article (PubMed ID: 18393913)
1. Hormone replacement therapy and stroke.
Billeci AM; Paciaroni M; Caso V; Agnelli G
Curr Vasc Pharmacol; 2008 Apr; 6(2):112-23. PubMed ID: 18393913
[TBL] [Abstract][Full Text] [Related]
2. Menopause and stroke and the effects of hormonal therapy.
Lobo RA
Climacteric; 2007 Oct; 10 Suppl 2():27-31. PubMed ID: 17882669
[TBL] [Abstract][Full Text] [Related]
3. The relevance of the Women's Health Initiative results on combined hormone replacement therapy in clinical practice.
Lemay A
J Obstet Gynaecol Can; 2002 Sep; 24(9):711-5. PubMed ID: 12360366
[TBL] [Abstract][Full Text] [Related]
4. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause.
Rossouw JE; Prentice RL; Manson JE; Wu L; Barad D; Barnabei VM; Ko M; LaCroix AZ; Margolis KL; Stefanick ML
JAMA; 2007 Apr; 297(13):1465-77. PubMed ID: 17405972
[TBL] [Abstract][Full Text] [Related]
5. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease.
Grodstein F; Manson JE; Colditz GA; Willett WC; Speizer FE; Stampfer MJ
Ann Intern Med; 2000 Dec; 133(12):933-41. PubMed ID: 11119394
[TBL] [Abstract][Full Text] [Related]
6. Postmenopausal hormone replacement therapy: scientific review.
Nelson HD; Humphrey LL; Nygren P; Teutsch SM; Allan JD
JAMA; 2002 Aug; 288(7):872-81. PubMed ID: 12186605
[TBL] [Abstract][Full Text] [Related]
7. Hormone therapy for preventing cardiovascular disease in post-menopausal women.
Main C; Knight B; Moxham T; Gabriel Sanchez R; Sanchez Gomez LM; Roqué i Figuls M; Bonfill Cosp X
Cochrane Database Syst Rev; 2013 Apr; (4):CD002229. PubMed ID: 23633307
[TBL] [Abstract][Full Text] [Related]
8. The effect of medroxyprogesterone acetate on estrogen-dependent risks and benefits--an attempt to interpret the Women's Health Initiative results.
Kuhl H; Stevenson J
Gynecol Endocrinol; 2006 Jun; 22(6):303-17. PubMed ID: 16785155
[TBL] [Abstract][Full Text] [Related]
9. Alternative hormone replacement regimens: is there a need for further clinical trials?
Welty FK
Curr Opin Lipidol; 2003 Dec; 14(6):585-91. PubMed ID: 14624135
[TBL] [Abstract][Full Text] [Related]
10. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin.
Heiss G; Wallace R; Anderson GL; Aragaki A; Beresford SA; Brzyski R; Chlebowski RT; Gass M; LaCroix A; Manson JE; Prentice RL; Rossouw J; Stefanick ML;
JAMA; 2008 Mar; 299(9):1036-45. PubMed ID: 18319414
[TBL] [Abstract][Full Text] [Related]
11. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study.
Shumaker SA; Legault C; Kuller L; Rapp SR; Thal L; Lane DS; Fillit H; Stefanick ML; Hendrix SL; Lewis CE; Masaki K; Coker LH;
JAMA; 2004 Jun; 291(24):2947-58. PubMed ID: 15213206
[TBL] [Abstract][Full Text] [Related]
12. Women's Health Initiative clinical trials: potential interactive effect of calcium and vitamin D supplementation with hormonal therapy on cardiovascular disease.
Jiang X; Nudy M; Aragaki AK; Robbins JA; Manson JE; Stefanick ML; OʼSullivan DM; Shikany JM; LeBlanc ES; Kelsey AM; Cauley J; Martin LW; Payne ME; Johnson KC; Howard B; Schnatz PF
Menopause; 2019 Aug; 26(8):841-849. PubMed ID: 31145202
[TBL] [Abstract][Full Text] [Related]
13. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial.
Anderson GL; Limacher M; Assaf AR; Bassford T; Beresford SA; Black H; Bonds D; Brunner R; Brzyski R; Caan B; Chlebowski R; Curb D; Gass M; Hays J; Heiss G; Hendrix S; Howard BV; Hsia J; Hubbell A; Jackson R; Johnson KC; Judd H; Kotchen JM; Kuller L; LaCroix AZ; Lane D; Langer RD; Lasser N; Lewis CE; Manson J; Margolis K; Ockene J; O'Sullivan MJ; Phillips L; Prentice RL; Ritenbaugh C; Robbins J; Rossouw JE; Sarto G; Stefanick ML; Van Horn L; Wactawski-Wende J; Wallace R; Wassertheil-Smoller S;
JAMA; 2004 Apr; 291(14):1701-12. PubMed ID: 15082697
[TBL] [Abstract][Full Text] [Related]
14. Post-menopausal hormone replacement therapy (cont'd): risk-benefit balance in the hot seat.
Prescrire Int; 2004 Jun; 13(71):106-9. PubMed ID: 15233153
[TBL] [Abstract][Full Text] [Related]
15. Transdermal hormone therapy and the risk of stroke and venous thrombosis.
Speroff L
Climacteric; 2010 Oct; 13(5):429-32. PubMed ID: 20670199
[TBL] [Abstract][Full Text] [Related]
16. Hormone replacement therapy in the post-Women's Health Initiative era. Report a a meeting held in Funchal, Madeira, February 24-25, 2003.
Burger H
Climacteric; 2003 May; 6 Suppl 1():11-36. PubMed ID: 12945798
[TBL] [Abstract][Full Text] [Related]
17. The Women's Health Initiative trial and related studies: 10 years later: a clinician's view.
Gurney EP; Nachtigall MJ; Nachtigall LE; Naftolin F
J Steroid Biochem Mol Biol; 2014 Jul; 142():4-11. PubMed ID: 24172877
[TBL] [Abstract][Full Text] [Related]
18. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial.
Rapp SR; Espeland MA; Shumaker SA; Henderson VW; Brunner RL; Manson JE; Gass ML; Stefanick ML; Lane DS; Hays J; Johnson KC; Coker LH; Dailey M; Bowen D;
JAMA; 2003 May; 289(20):2663-72. PubMed ID: 12771113
[TBL] [Abstract][Full Text] [Related]
19. [Clinical study of the month. Benefit/risk balance of postmenopausal estrogen-progestin treatment in peril in the Women's Health Initiative study: practical attitude of the clinician].
Gaspard U; van den Brûle F; Pintiaux A; Foidart JM
Rev Med Liege; 2002 Aug; 57(8):556-62. PubMed ID: 12405030
[TBL] [Abstract][Full Text] [Related]
20. Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women's Health Initiative randomized trial.
McTiernan A; Martin CF; Peck JD; Aragaki AK; Chlebowski RT; Pisano ED; Wang CY; Brunner RL; Johnson KC; Manson JE; Lewis CE; Kotchen JM; Hulka BS;
J Natl Cancer Inst; 2005 Sep; 97(18):1366-76. PubMed ID: 16174858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
